The impact of fusion genes on cancer stem cells and drug resistance
Autor: | Sivaramakrishnan Venkatabalasubramanian, Saurav Panicker, Surajit Pathak, Satish Ramalingam |
---|---|
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
Drug Oncogene Proteins Fusion media_common.quotation_subject medicine.medical_treatment Clinical Biochemistry Drug resistance Biology Targeted therapy Fusion gene 03 medical and health sciences 0302 clinical medicine Cancer stem cell medicine Animals Humans Molecular Biology media_common Lineage commitment Cell Biology General Medicine 030104 developmental biology Drug development Drug Resistance Neoplasm 030220 oncology & carcinogenesis Cancer cell Cancer research Neoplastic Stem Cells Genes Neoplasm |
Zdroj: | Molecular and cellular biochemistry. 476(10) |
ISSN: | 1573-4919 |
Popis: | With ever increasing evidences on the role of fusion genes as the oncogenic protagonists in myriad cancers, it's time to explore if fusion genes can be the next generational drug targets in meeting the current demands of higher drug efficacy. Eliminating cancer stem cells (CSC) has become the current focus; however, we have reached a standstill in drug development owing to the lack of effective strategies to eradicate CSC. We believe that fusion genes could be the novel targets to overcome this limitation. The intriguing feature of fusion genes is that it dominantly impacts every aspect of CSC including self-renewal, differentiation, lineage commitment, tumorigenicity and stemness. Given the clinical success of fusion gene-based drugs in hematological cancers, our attempt to target fusion genes in eradicating CSC can be rewarding. As fusion genes are expressed explicitly in cancer cells, eradicating CSC by targeting fusion genes provides yet an another advantage of negligible patient side effects since normal cells remain unaffected by the drug. We hereby delineate the latest evidences on how fusion genes regulate CSC and drug resistance. |
Databáze: | OpenAIRE |
Externí odkaz: |